Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR.
暂无分享，去创建一个
H. Goldschmidt | M. Dimopoulos | A. Palumbo | G. Gaidano | R. Hájek | A. Oriol | P. Moreau | W. Chng | H. Ludwig | T. Facon | L. Rosiñol | D. Joshua | C. Araujo | K. Weisel | L. Pour | T. Pika | H. Gillenwater | J. Straub | A. Suvorov | V. Goranova-Marinova